Preclinical proof-of-concept mouse xenografts demonstrated RAD 402’s strong tumor targeting with minimal bone/marrow uptake and expected hepatic clearance SYDNEY, March 27, 2026 (GLOBE NEWSWIRE)-- ...
Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its pipeline. DCC-3084, a pan-RAF inhibitor, “is no longer in our pipeline and we ...
NEW YORK, NY, UNITED STATES, February 9, 2026 /EINPresswire.com/ — With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results